Amended Statement of Beneficial Ownership (sc 13d/a)

Date : 11/22/2019 @ 9:49PM
Source : Edgar (US Regulatory)
Stock : Cocrystal Pharma Inc (COCP)
Quote : 0.71  0.0 (0.00%) @ 9:12AM

Amended Statement of Beneficial Ownership (sc 13d/a)

 

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Cocrystal Pharma, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
19188J300
(CUSIP Number)
Kate Inman
General Counsel, Secretary
OPKO Health, Inc.
4400 Biscayne Boulevard
Miami, Florida 33137
Telephone: (305) 575-4100

Phillip Frost, M.D.
Frost Gamma Investments Trust
Steven D. Rubin
4400 Biscayne Boulevard
Miami, Florida 33137
(305) 575-6015
(Name, address and telephone number of person authorized to receive notices and communications)
November 8, 2019
(Date of event which requires filing of this statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box  ¨.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.
*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 





CUSIP No. 19188J300
Schedule 13D
PAGE 2 of 9

1
 
NAME OF REPORTING PERSONS
 
OPKO Health, Inc.
2
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)  ¨        (b)  ¨
 
3
 
SEC USE ONLY
 
4
 
SOURCE OF FUNDS
 
WC
5
 
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) 
¨
6
 
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Delaware
NUMBER OF   SHARES
BENEFICIALLY OWNED BY
EACH REPORTING
PERSON
WITH
7
 
SOLE VOTING POWER 
 
 
2,659,685

(1) 
8
 
SHARED VOTING POWER
 
 
0

 
9
 
SOLE DISPOSITIVE POWER
 

 
 
2,659,685
(1) 
10
 
SHARED DISPOSITIVE POWER

 
 
0
 
11
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 

  
 
2,659,685
(1) 
12
 
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  ¨
13
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
 
7.6
%
(2) 
14
 
TYPE OF REPORTING PERSON
CO

(1) 
Includes 2,626,352 shares of common stock, par value $0.001 per share (the “Common Stock”), of Cocrystal Pharma, Inc. (the “Issuer”) and 33,333 shares of Common Stock underlying warrants.
(2) 
Calculated based on (i) 35,150,058 shares of Common Stock outstanding as of November 8, 2019, as reported by the Issuer on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2019 and (ii) 33,333 shares of Common Stock underlying warrants.





CUSIP No. 19188J300
Schedule 13D
PAGE 3 of 9

1
 
NAME OF REPORTING PERSONS
 
Phillip Frost, M.D.
2
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)  ¨        (b)  ¨
 
3
 
SEC USE ONLY
 
4
 
SOURCE OF FUNDS
 
OO
5
 
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) 
¨
6
 
CITIZENSHIP OR PLACE OF ORGANIZATION
 
United States of America
NUMBER OF   SHARES
BENEFICIALLY OWNED BY
EACH REPORTING
PERSON
WITH
7
 
SOLE VOTING POWER 
 
 
3,682,556
(1) 
8
 
SHARED VOTING POWER
 
 
0
 
9
 
SOLE DISPOSITIVE POWER
 

 
 
3,682,556
(1) 
10
 
SHARED DISPOSITIVE POWER

 
 
0
 
11
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 

  
 
3,682,556
(1) 
12
 
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  ¨
13
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
 
10.5
%
(2) 
14
 
TYPE OF REPORTING PERSON
IN

(1) 
Includes (i) 3,655,265 shares of Common Stock held by Frost Gamma Investments Trust (“FGIT”), which is controlled by Dr. Frost as sole trustee; and (ii) options to acquire 27,291 shares of Common Stock, which are exercisable within 60 days.





CUSIP No. 19188J300
Schedule 13D
PAGE 4 of 9

(2) 
Calculated based on (i) 35,150,058 shares of Common Stock outstanding as of November 8, 2019, as reported by the Issuer on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2019 and (ii) 27,291 shares of Common Stock issuable upon exercise of options exercisable within 60 days.





CUSIP No. 19188J300
Schedule 13D
PAGE 5 of 9

1
 
NAME OF REPORTING PERSONS
 
Frost Gamma Investments Trust
2
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)  ¨        (b)  ¨
 
3
 
SEC USE ONLY
 
4
 
SOURCE OF FUNDS
 
OO
5
 
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) 
¨
6
 
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Florida
NUMBER OF   SHARES
BENEFICIALLY OWNED BY
EACH REPORTING
PERSON
WITH
7
 
SOLE VOTING POWER 
 
 
3,655,265
 
8
 
SHARED VOTING POWER
 
 
0
 
9
 
SOLE DISPOSITIVE POWER
 

 
 
3,655,265
 
10
 
SHARED DISPOSITIVE POWER

 
 
0
 
11
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 

  
 
3,655,265
 
12
 
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  ¨
13
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
 
10.4
%
(1) 
14
 
TYPE OF REPORTING PERSON
OO

(1) 
Calculated based on 35,150,058 shares of Common Stock outstanding as of November 8, 2019, as reported by the Issuer on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2019.





CUSIP No. 19188J300
Schedule 13D
PAGE 6 of 9

1
 
NAME OF REPORTING PERSONS
 
Steven D. Rubin
2
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)  ¨        (b)  ¨
 
3
 
SEC USE ONLY
 
4
 
SOURCE OF FUNDS
 
OO
5
 
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) 
¨
6
 
CITIZENSHIP OR PLACE OF ORGANIZATION
 
United States of America
NUMBER OF   SHARES
BENEFICIALLY OWNED BY
EACH REPORTING
PERSON
WITH
7
 
SOLE VOTING POWER 
 
 
51,739

(1) 
8
 
SHARED VOTING POWER
 
 
0

 
9
 
SOLE DISPOSITIVE POWER
 

 
 
51,739

(1) 
10
 
SHARED DISPOSITIVE POWER

 
 
0
 
11
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 

  
 
51,739
(1) 
12
 
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  ¨
13
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
 
0.1
%
(2) 
14
 
TYPE OF REPORTING PERSON
IN

(1) 
Includes 24,448 shares of Common Stock and (ii) 27,291 shares of Common Stock issuable upon exercise of options exercisable within 60 days.
(2) 
Calculated based on (i) 35,150,058 shares of Common Stock outstanding as of November 8, 2019, as reported by the Issuer on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2019 and (ii) 27,291 shares of Common Stock issuable upon exercise of options exercisable within 60 days.





CUSIP No. 19188J300
Schedule 13D
PAGE 7 of 9

EXPLANATORY NOTE
This Amendment No. 1 (the “Amendment”) to Schedule 13D is being filed with the Securities and Exchange Commission (the “SEC”) on behalf of the Reporting Persons (as defined below) and relates to the common stock, par value $0.001 per share (the “Common Stock”), of Cocrystal Pharma, Inc. (the “Issuer”). This Amendment is being filed solely as a result of a change in the Issuer’s issued and outstanding Common Stock and amends and supplements the statement on Schedule 13D filed by OPKO Health, Inc., a Delaware corporation (“OPKO”), Phillip Frost, M.D. (“Dr. Frost”), Frost Gamma Investments Trust (“FGIT”), and Steven D. Rubin (“Mr. Rubin”)(collectively, the “Reporting Persons”) with the SEC on May 9, 2019 (the “May 2019 Schedule 13D”), which amended and restated the (i) Schedule 13D originally filed on December 5, 2014 filed jointly by OPKO, Dr. Frost, FGIT, Mr. Rubin and certain other persons (the “Original 13D”), as amended with respect to Dr. Frost, FGIT, Mr. Rubin and certain other persons by Amendment No. 1 filed on June 19, 2018 and Amendment No. 2 filed on March 19, 2019, and (ii) Schedule 13G filed by OPKO on May 10, 2017, as amended on February 2, 2018 and February 14, 2019. This Amendment is being filed solely by the Reporting Persons and does not amend or supplement the Original 13D or any other amendments thereto with respect to any other persons that jointly filed the Original 13D with the Reporting Persons. Except as set forth herein, this Amendment does not modify any of the information previously reported by the Reporting Persons in the May 2019 Schedule 13D. Unless otherwise indicated, all capitalized terms used herein have the meanings ascribed to them in the May 2019 Schedule 13D.


ITEM 5.
Interest in Securities of the Issuer.
Items 5(a)-(c) are hereby amended and restated to read as follows:
(a)
OPKO is the beneficial owner of and directly holds 2,626,352 shares of Common Stock and 33,333 shares of Common Stock underlying warrants or approximately 7.6% of the Issuer’s issued and outstanding Common Stock, based on 35,150,058 shares outstanding as of November 8, 2019 as reported by the Issuer on Form 10-Q filed with the SEC on November 12, 2019, and 33,333 shares of Common Stock underlying warrants.
Richard Lerner, M.D. (“Dr. Lerner”), a director of OPKO, is a stockholder of the Issuer. Dr. Frost, Jane H. Hsiao, PhD., MBA (“Dr. Hsiao”), Vice Chairman of the Board and Chief Technical Officer of OPKO, and Mr. Rubin, Executive Vice President-Administration and a director of OPKO, are directors of the Issuer. OPKO’s reported ownership does not include securities beneficially owned by FGIT, Drs. Lerner, Frost, and Hsiao, and Mr. Rubin. OPKO disclaims beneficial ownership of the securities of the Issuer owned by FGIT, Drs. Lerner, Frost, and Hsiao and Mr. Rubin. Drs. Hsiao and Lerner beneficially own securities of the Issuer as follows:
Name
 
Number of Shares of Common Stock
Beneficially Owned
 
Sole or Shared
Voting Power
 
Sole or Shared
Dispositive Power
 
Percentage of Class
Jane H. Hsiao, Ph.D., MBA
 
325,021
(1) 
 
Sole
 
Sole
 
0.9
%
(2) 
Richard A. Lerner, M.D.
 
108,696
 
 
Shared(3)
 
Shared(3)
 
0.3
%
(4) 
(1) 
Comprised of (i) 114,509 shares of Common Stock owned directly by Dr. Hsiao; (ii) 183,221 shares of Common Stock owned by Hsu Gamma Investment, L.P., of which Dr. Hsiao is the general partner; and (iii) and options to acquire 27,291 shares of Common Stock, which are exercisable within 60 days. The stock options were received as a result of Dr. Hsiao’s service as a director of the Issuer. Dr. Hsiao disclaims beneficial ownership of shares of Common Stock owned by Hsu Gamma Investment, L.P., except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.





CUSIP No. 19188J300
Schedule 13D
PAGE 8 of 9

(2) Calculated based on (i) 35,150,058 shares of Common Stock outstanding as of November 8, 2019, as reported by the Issuer on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2019 and (ii) 27,291 shares of Common Stock issuable upon exercise of options exercisable within 60 days.
(3) 
Held through Lerner Family Trust, Richard A & Nicole G Lerner Trustees.
(4) 
Calculated based on (i) 35,150,058 shares of Common Stock outstanding as of November 8, 2019, as reported by the Issuer on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2019.
Dr. Frost holds 27,291 shares of Common Stock issuable upon exercise of options exercisable within 60 days. Dr. Frost, as the sole trustee of FGIT, may be deemed to beneficially own the 3,655,265 shares of Common Stock beneficially owned by FGIT. The 3,682,556 shares of Common Stock beneficially owned by Dr. Frost constitute approximately 10.5% of the Issuer’s issued and outstanding shares, based on (i) 35,150,058 shares of Common Stock outstanding as of November 8, 2019, as reported by the Issuer on Form 10-Q filed with the SEC on November 12, 2019 and (ii) 27,291 shares of Common Stock issuable upon exercise of options exercisable within 60 days. FGIT holds 3,655,265 shares of Common Stock or approximately 10.4% of the Issuer’s issued and outstanding shares, based on 35,150,058 shares of Common Stock outstanding as of November 8, 2019, as reported by the Issuer on Form 10-Q filed with the SEC on November 12, 2019. Dr. Frost and FGIT’s reported ownership does not include securities owned by OPKO. Dr. Frost and FGIT each disclaim beneficial ownership of the securities of the Issuer owned by OPKO.
Mr. Rubin holds 24,448 shares of Common Stock and (ii) 27,291 shares of Common Stock issuable upon exercise of options exercisable within 60 days or approximately 0.1% of the Issuer’s issued and outstanding shares, based on (i) 35,150,058 shares of Common Stock outstanding as of November 8, 2019, as reported by the Issuer on Form 10-Q filed with the SEC on November 12, 2019 and (ii) 27,291 shares of Common Stock issuable upon exercise of options exercisable within 60 days. Mr. Rubin’s Common Stock ownership was previously erroneously reported as 23,448.
(b)
OPKO beneficially owns and has sole power to vote and dispose of 2,626,352 shares of Common Stock and 33,333 shares of Common Stock underlying warrants.
Dr. Frost, as the sole trustee of FGIT, has sole voting and dispositive power over 3,655,265 shares of Common Stock beneficially owned by FGIT. Dr. Frost individually owns and has sole voting and dispositive power with respect to 27,291 shares of Common Stock issuable upon exercise of options exercisable within 60 days.
FGIT directly beneficially owns 3,655,265 shares of Common Stock. Dr. Frost is the sole trustee of FGIT and has sole voting and dispositive power with respect to 3,655,265 shares of Common Stock.
Mr. Rubin individually owns and has sole power to vote and dispose with respect to 24,448 shares of Common Stock and 27,291 shares of Common Stock issuable upon exercise of options exercisable within 60 days.
(c)
There have been no transactions in the Common Stock effected by OPKO, Dr. Frost, FGIT, or Mr. Rubin in the last 60 days.






CUSIP No. 19188J300
Schedule 13D
PAGE 9 of 9

SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OPKO Health, Inc.
 
 
 
 
 
Dated:
November 22, 2019
 
 
 
By:
 
/s/ Kate Inman
 
 
 
 
 
Name:
 
Kate Inman
 
 
 
 
 
Title:
 
General Counsel, Secretary
 
 
 
 
 
 
 
 
 
 
 
 
 
Phillip Frost, M.D.
 
 
 
 
 
Dated:
November 22, 2019
 
 
 
By:
 
/s/ Phillip Frost, M.D.
 
 
 
 
 
Name:
 
Phillip Frost, M.D.
 
 
 
 
 
 
 
 
 
 
 
 
 
Frost Gamma Investments Trust
 
 
 
 
 
Dated:
November 22, 2019
 
 
 
By:
 
/s/ Phillip Frost, M.D.
 
 
 
 
 
Name:
 
Phillip Frost, M.D.
 
 
 
 
 
Title:
 
Trustee
 
 
 
 
 
 
 
 
 
 
 
 
 
Steven D. Rubin
 
 
 
 
 
Dated:
November 22, 2019
 
 
 
By:
 
/s/ Steven D. Rubin
 
 
 
 
 
Name:
 
Steven D. Rubin
 
 
 
 
 
 
 
 


Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart

1 Year : From Apr 2019 to Apr 2020

Click Here for more Cocrystal Pharma Charts.

Cocrystal Pharma (NASDAQ:COCP)
Intraday Stock Chart

Today : Wednesday 1 April 2020

Click Here for more Cocrystal Pharma Charts.

Latest COCP Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


$
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.